Zacks Investment Research downgraded NICOX SA EUR1 (NASDAQ:NICXF) to Hold in a statement released earlier today.
- Updated: September 24, 2016
Zacks Investment Research has downgraded NICOX SA EUR1 (NASDAQ:NICXF) to Hold in a report released on 09/22/2016.
Yesterday NICOX SA EUR1 (NASDAQ:NICXF) traded 0.00% even at $10.74. The company’s 50-day moving average is $11.89 and its 200-day moving average is $10.81. The last closing price is down -0.64% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 0 shares of the stock were exchanged, down from an avg. volume of 1,855
With a market capitalization of $0, NICOX SA EUR1 has one year low of $2.29 and a 52 week high of $14.75 .
Brief Synopsis About NICOX SA EUR1 (NASDAQ:NICXF)
Nicox SA, an ophthalmic company, develops and markets various ophthalmic products to enhance eye sight. The company offers AdenoPlus, an in vitro diagnostic medical device that aids in the differential diagnosis of acute conjunctivitis; Xailin, a range of ocular products, such as medical devices, including ocular lubricants for dry eye symptoms and eyewash; and Zared Chocolate, a dark chocolate combining vitamins and minerals, such as zinc. Its products pipeline includes latanoprostene bunod, a drug-candidate based on its nitric oxide (NO)-donating research platform, is in Phase III clinical trials for the treatment of glaucoma and ocular hypertension; and AC-170, a formulation of cetirizine for the treatment of allergic conjunctivitis. The companyÂ’s products pipeline also comprises NCX 4251, a form of fluticasone propionate for blepharitis; NCX 470, a NO donating bimatoprost for preclinical models of glaucoma and ocular hypertension; and NO-steroids for various eye diseases, such as diabetic macular edema and retinal vein occlusion. In addition, its products pipeline includes AzaSite to treat bacterial conjunctivitis; BromSite for the treatment of inflammation and prevention of pain after cataract surgery; and Carragelose, an eye drop for viral conjunctivitis. It has collaboration with AstraZeneca, Pfizer, Merck, and Bausch + Lomb; and license agreement with InSite Vision Inc. The company serves directly in Germany, France, the United Kingdom, Italy, and Spain, as well as through distributors internationally. Nicox SA was founded in 1996 and is headquartered in Valbonne, France.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.